Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases

Ruben A. Mesa, Chin Yang Li, Rhett P. Ketterling, Georgene S. Schroeder, Ryan A. Knudson, Ayalew Tefferi

Research output: Contribution to journalArticle

254 Citations (Scopus)

Abstract

Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), MO (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.

Original languageEnglish (US)
Pages (from-to)973-977
Number of pages5
JournalBlood
Volume105
Issue number3
DOIs
StatePublished - Feb 1 2005

Fingerprint

Primary Myelofibrosis
Chemotherapy
Core Binding Factors
Chromosomes
Genes
Health
Acute Myeloid Leukemia
Chromosomes, Human, Pair 5
Induction Chemotherapy
Chromosomes, Human, Pair 7
Karyotype
Cytogenetics
Chronic Disease
Therapeutics
Clinical Trials
Drug Therapy
Survival
Mortality
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Leukemic transformation in myelofibrosis with myeloid metaplasia : A single-institution experience with 91 cases. / Mesa, Ruben A.; Li, Chin Yang; Ketterling, Rhett P.; Schroeder, Georgene S.; Knudson, Ryan A.; Tefferi, Ayalew.

In: Blood, Vol. 105, No. 3, 01.02.2005, p. 973-977.

Research output: Contribution to journalArticle

Mesa, Ruben A. ; Li, Chin Yang ; Ketterling, Rhett P. ; Schroeder, Georgene S. ; Knudson, Ryan A. ; Tefferi, Ayalew. / Leukemic transformation in myelofibrosis with myeloid metaplasia : A single-institution experience with 91 cases. In: Blood. 2005 ; Vol. 105, No. 3. pp. 973-977.
@article{c12974cbe1f6415f8c141bf025c0f0e6,
title = "Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases",
abstract = "Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4{\%}), MO (22.4{\%}), and M2 (17.9{\%}). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91{\%}): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98{\%} of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41{\%} reverted into chronic-phase disease and the incidence of treatment-related mortality was 33{\%}. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.",
author = "Mesa, {Ruben A.} and Li, {Chin Yang} and Ketterling, {Rhett P.} and Schroeder, {Georgene S.} and Knudson, {Ryan A.} and Ayalew Tefferi",
year = "2005",
month = "2",
day = "1",
doi = "10.1182/blood-2004-07-2864",
language = "English (US)",
volume = "105",
pages = "973--977",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Leukemic transformation in myelofibrosis with myeloid metaplasia

T2 - A single-institution experience with 91 cases

AU - Mesa, Ruben A.

AU - Li, Chin Yang

AU - Ketterling, Rhett P.

AU - Schroeder, Georgene S.

AU - Knudson, Ryan A.

AU - Tefferi, Ayalew

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), MO (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.

AB - Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), MO (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.

UR - http://www.scopus.com/inward/record.url?scp=12844284481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844284481&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-07-2864

DO - 10.1182/blood-2004-07-2864

M3 - Article

C2 - 15388582

AN - SCOPUS:12844284481

VL - 105

SP - 973

EP - 977

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -